

Program

Sunday, October 5

Registration will open at 16:30

18:00-19:00 Welcome Reception

5F WILLARD

Monday, October 6

9:00-11:00 Symposium 1

5F WILLARD

Cancer Immunotherapy: Antibody, T cell and Natural Immunity

*Chairpersons: **Jean-Pierre Mach**, University of Lausanne, Switzerland*

***Hiroshi Shiku**, Mie University, Japan*

- S1-01 Cancer Immunotherapy: Cancer Vaccines and T cell Therapy
Hiroshi Shiku, Mie University, Japan
- S1-02 Antibody Targeted MHC or CD1d Fusion Proteins as a New Cancer Immunotherapy Strategy
Jean-Pierre Mach, University of Lausanne, Switzerland
- S1-03 Exploration of Novel Tumor Antigens and Translational Study of Peptide-based Cancer Vaccine -from Bench to Bedside and Lesson from Bedside-
Toshihiko Torigoe, Sapporo Medical University, Japan
- S1-04 Activation of Innate Immune Response Mediated by DNA-triggered Danger Signals
Akinori Takaoka, Hokkaido University, Japan

11:00-11:30 Poster Presentation & Coffee Break

5F MAY FAIR

11:30-12:30 Plenary Lecture 1

5F WILLARD

*Chairperson: **Minoru Toyota**, Sapporo Medical University, Japan*

- PL1 Epigenetic Profiling and Epigenetic Therapy in Cancer
Jean-Pierre Issa, University of Texas, MD Anderson Cancer Center, USA

12:30-13:30 Luncheon 1

5F WILLARD

ProGRP, A Biomarker for Small Cell Lung Cancer

Co-sponsored by Abbott Laboratories

*Chairperson: **Petra Stieber**, University of Munich, Germany*

- L1-01 Automated Chemiluminescent Immunoassay of ProGRP
Barry Dowell, Abbott Laboratories, USA
- L1-02 Clinical Evaluation of the ARCHITECT® ProGRP assay
Petra Stieber, University of Munich, Germany

13:30-15:30 Symposium 4

5F WILLARD

New Molecular Markers for Colon Cancer

Chairpersons: John E. Shively, Beckman Research Institute of the City of Hope, USA

Yuji Hinoda, Yamaguchi University Graduate School of Medicine, Japan

- S4-01 Copper-64 PET Imaging in an Animal Model with Anti-CEA and Anti-VEGF Antibodies
John E. Shively, Beckman Research Institute of the City of Hope, USA
- S4-02 MicroRNA Expression Profiles Associated with Prognosis and Therapeutic Outcome in Colon Adenocarcinoma
Aaron J. Schetter, NCI, National Institute of Health, USA
- S4-03 Proteomic Approaches to Biomarker and Therapy Target Discovery for Colorectal Cancer
Tesshi Yamada, National Cancer Center Research Institute, Japan
- S4-04 Polymorphisms of UGT1A1 are the Useful Predictive Markers for the Toxicity of Irinotecan
Shoichi Hazama, Yamaguchi University Graduate School of Medicine, Japan

13:30-15:30 Symposium 6

4F CARLTON

Translational Research of Cancer Therapy and Diagnosis

Chairpersons: Masahide Kuroki, Fukuoka University, Japan

Tomas Zima, Charles University, Czech Republic

- S6-01 Phase I Clinical Trial of Glypican-3 Peptide Vaccine in Patients with Hepatocellular Carcinoma
Tetsuya Nakatsura, National Cancer Center Hospital East, Japan
- S6-02 Phase I Study of BK-UM (CRM197) in Patients with Ovarian Cancer
Shingo Miyamoto, Fukuoka University, Japan
- S6-03 The Dynamics of Serum Biomarkers and Their Role in Predicting Metastatic Uveal Melanoma
Vivian Barak, Hadassah - Hebrew University Medical Center, Israel
- S6-04 Histone Deacetylase Inhibitor FK228 Enhances Adenovirus-mediated p53 Family Gene Therapy in Cancer Models
Yasushi Sasaki, Sapporo Medical University, Japan

15:30-16:00 Poster Presentation & Coffee Break

5F MAY FAIR

16:00-18:00 Symposium 7

5F WILLARD

Molecular Biology and Clinical Significance of Serpins in Malignancy

Chairpersons: Hiroshi Kato, Life Network Laboratory, Japan

Hans Bonfrer, Antoni van Leeuwenhoekhuis, Netherlands

- S7-01 Biological Function and Clinical Significance of a Serological Tumor Marker, Squamous Cell Carcinoma Antigen in Squamous Cell Carcinoma of the Uterine Cervix
Shugo Nawata, Yamaguchi University Graduate School of Medicine, Japan

- S7-02 Maspin as a Tumor Suppressing Serpin
Ming Zhang, Northwestern University Feinberg School of Medicine, USA
- S7-03 PAI-1 and uPA as Biomarkers in Breast Cancer: From Pilot Studies to Recommendation for Clinical Use
Michael J. Duffy, St. Vincent's University Hospital, Ireland
- S7-04 Squamous Cell Carcinoma Antigen (SCCA) 1 and 2 Expression Kinetics in Cultured Normal Peripheral Blood Mononuclear Cells (PBMC)
Magdalena Chechlinska, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Poland

16:00-18:00 Symposium 8

4F CARLTON

New Molecular Markers in Lung Cancer

Co-sponsored by Abbott Laboratories

Chairpersons: Petra Stieber, University of Munich, Germany

Ken Yamaguchi, Shizuoka Cancer Center, Japan

- S8-01 CEA, CYFRA 21-1, NSE and ProGRP in the Diagnosis of Lung Cancer – A Multivariate Approach
Petra Stieber, University of Munich, Germany
- S8-02 ProGRP and Peptide-screening Approach to the Discovery of New Tumor Markers
Ken Yamaguchi, Shizuoka Cancer Center, Japan
- S8-03 The Role of ADAM9 in Metastasis of Non-small Cell Lung Cancer
Nariaki Matsuura, Osaka University, Japan
- S8-04 Progastrin Releasing Peptide in Serum and Plasma from SCLC Patients and Normal Individuals
Marianne S. Nordlund, Rikshospitalet Medical Centre, Norway

18:00-19:00 Special Presidential Forum

5F WILLARD

Rear View Perspectives on Pivotal Science within ISOBM

Chairpersons: Kohzoh Imai, Sapporo Medical University, Japan

Torgny Stigbrand, Umeå University, Sweden

- SPF1 From Analbuminemic Rats to Pierisin, An Apoptogenic Peptide from Butterflies
Takashi Sugimura, National Cancer Center, Japan
- SPF2 From “Placental Alkaline Phosphatase” to “Oncodevelopmental Biology” to the “Burnham Institute for Medical Research” - A Success Story
José Luis Millan, Burnham Institute for Medical Research, USA
- SPF3 From the Study of Carcinoembryonic Proteins to Molecular Medicine
Sabine von Kleist, University of Freiburg, Germany

19:30- ISOBM Historical Party

4F LE GRAND

8:40-11:00 **Symposium 2**

5F WILLARD

New Perspective of Cancer Stem Cells

*Chairpersons: **Stewart Sell**, New York State Health Department, Wadsworth Center, USA*

***Tetsu Akiyama**, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Japan*

S2-01 Cancer Stem Cells

Stewart Sell, Wadsworth Center and Ordway Research Institute, USA

S2-02 Stemness in Normal and Malignant Tissues

Atsushi Hirao, Cancer Research Institute, Kanazawa University and CREST, JST, Japan

S2-03 Leukemic Stem Cells: New Therapeutic Targets?

Dominique Bonnet, Cancer Research UK, London Research Institute, UK

S2-04 "Stemness" Genomics Law Defines Epigenetic Boundaries of Death-from-cancer Phenotypes of Human Cancer

Gennadi V. Glinsky, Ordway Research Institute, Albany Medical College, USA

S2-05 Insufficient Radiofrequency Ablation Therapy May Induce Further Malignant Transformation of Hepatocellular Carcinoma

Nobuyuki Matsumoto, St. Marianna University School of Medicine, Japan

9:00-10:30 **Workshop 1**

4F CARLTON

Breast Cancer

*Chairpersons: **Vivian Barak**, Hadassah - Hebrew University Medical Center, Israel
Kjell Nustad, Norwegian Radium Hospital, Norway*

W1-01 Efficacy of Cross-reacting Material 197 (CRM197), a Specific Inhibitor for Heparin-binding Epidermal Growth Factor-like Growth Factor (HB), in Breast Cancer Patients

Fusanori Yotsumoto, Fukuoka University, Japan

W1-02 Prognostic Significance of Cytokeratin Markers in Breast Cancer –a Meta Analysis

Vivian Barak, Hadassah - Hebrew University Medical Center, Israel

W1-03 CEACAM1, a Cell-cell Adhesion Molecule, Modulates Differentiation of Breast Cancer Cells

Shozo Yokoyama, Beckman Research Institute of the City of Hope National Medical Center, USA

W1-04 Molecular Analysis of Circulating Tumor Cells: Clinical Implications

Winfried H Albert, AdnaGen AG, Ostpassage, Germany

W1-05 Detection of Oligometastases in Breast Cancer by using Tumormarkers

Petra Stieber, University of Munich, Germany

W1-06 HER-2/neu Oncoprotein Serum Levels in Patients with Breast Cancer: Comparison with CEA and CA 15.3

Rafael Molina, Oncobiology Unit, Hospital Clinic, Medical School, Barcelona, Spain

11:00-11:30 **Poster Presentation & Coffee Break**

5F MAY FAIR

11:30-12:30 **Plenary Lecture 2**

5F WILLARD

Chairperson: **Herbert Z. Kupchik**, USA

PL2 Large-scale Mutational Analyses of Human Cancers: Lessons Learned from Sequencing Cancer Genomes

D Will Parsons, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
Texas Children's Cancer Center, Baylor College of Medicine, USA

13:00- **Excursion**

Meet at the lobby on the 1st floor at 12:50

Wednesday, October 8

9:00-11:00 **Symposium 9**

5F WILLARD

New Markers

Chairpersons: **Rafael Molina**, Oncobiology Unit, Hospital Clinic, Medical School, Barcelona, Spain

Michael J. Duffy, St. Vincent's University Hospital, Ireland

- S9-01 The Future of Tumor Markers: New Technologies and New Approaches
Michael J. Duffy, St. Vincent's University Hospital, Ireland
- S9-02 PCA3 and TMPRSS2 Gene Fusion Markers for Prostate Cancer
Harry Rittenhouse, Gen-Probe Incorporated, USA
- S9-03 Tumor Markers in the Diagnosis of Unknown Primary Malignancy
Rafael Molina, Oncobiology Unit, Hospital Clinic, Medical School, Barcelona, Spain
- S9-04 Application of a Novel Dual Biomarker Algorithm for Differential Diagnosis in Patients with an Adnexal Mass
W. Jeffrey Allard, Fujirebio Diagnostics, Inc., USA
- S9-05 M1/MUC5AC Mucin: a Biomarker of the Precancerous Pancreas
Jacques Bara, INSERM, France

9:00-9:45 **Workshop 2**

4F CARLTON

New Therapy with Small Molecules

Chairpersons: **José Luis Millán**, Burnham Institute for Medical Research, USA
Tatsuro Irimura, University of Tokyo, Japan

- W2-01 The Inhibition of Amphiregulin Blocks AKT as well as ERK Activations in Pancreatic Cancer
Tatsuya Fukami, Fukuoka University, Japan
- W2-02 Pharmacological Modulation of Alkaline Phosphatase Function
José Luis Millán, Burnham Institute for Medical Research, USA
- W2-03 Human Counterpart of Epiglycanin/ Muc21 as a Potential Marker for Thyroid Carcinoma Progression
Kyoko Okada, The University of Tokyo, Japan

9:45-11:00 Workshop 3

4F CARLTON

Personalized Medicine in Oncology

Chairpersons: **Reiji Kannagi**, Aichi Cancer Center, Japan

Hiroyuki Yamamoto, Sapporo Medical University, Japan

W3-01 Epigenetic Silencing of microRNA-34b/c and BTG4 is Associated with CpG Island Hypermethylation in Colorectal Cancer

Hiromu Suzuki, Sapporo Medical University, Japan

W3-02 Development of a Human Tumor Tissue Culture System that Mimics Nitric Oxide Synthase Expression of Tumors Arising in the Tongue

James A. Radosevich, University of Illinois at Chicago, USA

W3-03 A Novel Transmembrane Mucin Muc21/Epiglycanin: Distribution and Glycosylation

Mayumi Hoshino, The University of Tokyo, Japan

W3-04 The Gene Silencing Due to Hypermethylation of Promoter CpG Island Tend to be Induced in the Common Target Genes for Both EZH2 and DNMTs

Hiroaki Taniguchi, Spanish National Cancer Research Center, Spain and Sapporo Medical University, Japan

W3-05 Cell Culture PET (CC-PET): an In-vitro Model for Explanation of Irradiation Induced F-18 FDG Uptake in Cancer Cells for Cell Repair as Shown by Positron-emission-tomography (PET)

Peter Oehr, University Bonn, Germany

W3-06 TNF- α in Radicular and Keratocyst of Maxillofacial Region

Vladimir Jurisic, University of Belgrade, Serbia

11:00-11:30 Poster Presentation & Coffee Break

5F MAY FAIR

11:30-12:30 Plenary Lecture 3

5F WILLARD

Chairperson: **John E. Shively**, Beckman Research Institute of the City of Hope, USA

PL3 The New Phase of Transcriptome Analysis

Yoshihide Hayashizaki, RIKEN, Japan

12:30-13:30 Luncheon 2

5F WILLARD

Chemo-and Biologic Therapy for Gastric Cancer

Co-sponsored by TAIHO PHARMACEUTICAL CO., LTD.

Chairperson: **Yasuhisa Shinomura**, Sapporo Medical University, Japan

L2-01 Chemo-and Biologic Therapy for Gastric Cancer

Atsushi Ohtsu, National Cancer Center Hospital East, Japan

13:30-14:30 ISOBM Abbott Award

5F WILLARD

Chairperson: **Torgny Stigbrand**, Umeå University, Sweden

Clinical Aspects of α -fetoprotein and Its Sugar Chain

Kazuhisa Taketa, Emeritus Professor Okayama University, Japan

14:30-15:30 General Assembly

5F WILLARD

15:30-16:00 Poster Presentation & Coffee Break

5F MAY FAIR

16:00-18:15 Symposium 5

5F WILLARD

Gene Expression and Molecular Diagnostics

Chairpersons: Phil Rye, Diagenic, Norway

Fumio Itoh, St. Marianna University School of Medicine, Japan

- S5-01 The Development of a Blood-Based Gene Expression Test for the Early Detection of Breast Cancer
Anders Lönneborg, DiaGenic ASA, Norway
- S5-02 Molecular Analysis of Hard-to-identify Tumors Using the Pathwork® Tissue of Origin (TOO) Test
C.Ted Rigl, Pathwork Diagnostics, USA
- S5-03 Cancelled
- S5-04 Single and Multiplex Gene Expression Assays: Applications for Biomarker Discovery & Validation for Molecular Diagnostics
Gary K. McMaster, Panomics Inc., USA

16:00-17:00 Workshop 4

4F CARLTON

Prostate Cancer

Co-sponsored by Abbott Laboratories

Chairpersons: Ulf-Hakan Stenman, Helsinki University Central Hospital, Finland

Toshihiko Torigoe, Sapporo Medical University, Japan

- W4-01 Utility of Free/total PSA Ratio to Detect Clinically Significant Prostate Cancer in a Normal Population with Lower PSA Level
Yoichi Arai, Tohoku University, Japan
- W4-02 Diagnostic Value of Free PSA at Low PSA Concentrations
Ulf-Hakan Stenman, Helsinki University Central Hospital, Finland
- W4-03 A Novel Method of Diagnosing Prostate Cancer with Low PSA Level by Using Lectin and Anti-PSA Antibody
Toshihiko Torigoe, Sapporo Medical University, Japan

17:00-18:15 Workshop 5

4F CARLTON

Gastric Cancer and Hepatocarcinoma Cancer

Chairpersons: Elliot Alpert, UCSD Medical Center, USA

Yutaka Aoyagi, Niigata University, Japan

- W5-01 Gamma-Glutamyl-Carboxylase Regulates Development of Hepatocellular Carcinoma
Hidenori Shiraha, Okayama University Medical School, Japan
- W5-02 RECAF as a Cancer Marker for Gastrointestinal Diseases
Ricardo Moro, BioCurex, Canada
- W5-03 Cancelled
- W5-04 The Potential Utility of Lectin Score to Predict Intraperitoneal Free Cancer Cell (IFCC) by Fluorescein-based Lectin Microarray in Advanced Gastric Cancer
Keishi Yamashita, Kitasato University Hospital and New Energy and Industrial Technology Development Organization (NEDO), Japan

- W5-05 DNA Methylation Analysis of Gastric Washes as a New Molecular Diagnostic Tool for Gastric Cancer
Yoshiyuki Watanabe, University of Texas MD Anderson Cancer Center, USA and St. Marianna University School of Medicine, Japan
- W5-06 Epigenetic Silencing of Interferon Regulatory Factor (IRF) Family Genes in Colorectal and Gastric Cancer
Masaki Yamashita, Sapporo Medical University and St. Marianna University School of Medicine, Japan

19:30- **Banquet**

5F WILLARD

Thursday, October 9

9:00-10:00 **Workshop 6**

5F WILLARD

Targeting Therapy of Colon Cancer

*Chairpersons: **Masahiko Watanabe**, Kitasato University, Japan
Yasushi Adachi, Sapporo Medical University, Japan*

- W6-01 β -catenin is a Sensible Therapeutic Marker of Cancer
Bo Liu, University of Pittsburgh, USA
- W6-02 Frizzled-7 as a Potential Therapeutic Target in Colorectal Cancer
Koji Ueno, Yamaguchi University Graduate School of Medicine, Japan
- W6-03 Treatment with a New IGF-I Receptor Tyrosine Kinase Inhibitor for Human Colorectal Carcinomas
Yasushi Adachi, Sapporo Medical University, Japan and Sapporo Shirakaba-dai Hospital, Japan
- W6-04 Cancelled

9:00-10:30 **Workshop 7**

4F CARLTON

Ovarian Cancer and Prostate Cancer

*Chairpersons: **Catharine M. Sturgeon**, Umeå University, Sweden
Kokichi Sugano, Tochigi Cancer Center, Japan*

- W7-01 β 1,3-galactosyltransferase-4/5 as Novel Serological Tumor Markers for Gynecologic Cancers
Akira Seko, Tokyo Institute of Technology, Japan
- W7-02 Anti-PSMA Antibodies as Novel Agents for Targeting Prostate Cancer
Ursula Elsässer-Beile, University of Freiberg, Germany
- W7-03 A PSMAxCD3 Diabody Effectively Eliminates PSMA-positive Prostate Cancer Cells by Redirecting and Activating T-cells
Patrick Bühler, University of Freiberg, Germany
- W7-04 A Novel Diagnostic Biomarker, LMP2, for Human Uterine Leiomyosarcoma
Takuma Hayashi, Shinshu University Graduate School of Medicine, Japan
- W7-05 Serum Protein Profiling by Mass Spectrometry Provides Diagnostic Information Independently of CA125 in Women with a Pelvic Mass
Jonna Skov Madsen, Vejle County Hospital, Denmark

W7-06 Cancelled

W7-07 The Dynamics of PSA during Hormone-Refractory Prostate Cancer (HRPC)
Chemotherapy (CT)

Natalia S. Sergeeva, Moscow Herzen Research Oncological Institute,
Russia

10:00-12:00 Symposium 3

5F WILLARD

Advances in the Epigenetic World

Co-sponsored by Chugai Pharmaceutical Co., Ltd.

Chairpersons: Jean-Pierre Issa, M. D. Anderson Cancer Center, USA

Minoru Toyota, Sapporo Medical University, Japan

S3-01 Genome-wide DNA Methylation Mapping in Cancer

Lanlan Shen, M.D. Anderson Cancer Center, USA

S3-02 Epigenetic Field for Gastric Cancerization, and Its Induction by *Helicobacter Pylori*
Infection

Toshikazu Ushijima, National Cancer Center Research Institute, Japan

S3-03 Epigenetic Gene Silencing and microRNA in Human Colon Cancer

Minoru Toyota, Sapporo Medical University, Japan

S3-04 Epigenetic Contributions to Chronic Lymphocyte Leukemia

Christoph Plass, German Cancer Research Center, Germany

10:20-10:50 Poster Presentation & Coffee Break

5F MAY FAIR

12:00- Closing Ceremony

5F WILLARD

Monday, October 6

11:00-11:30 Poster Session 1

Lung Cancer and Prostate Cancer

- P1-01 Plasma Free Amino Acid Profiling as a Novel Screening Marker for Non Small Cell Lung Cancer (NSCLC)
Masahiko Higashiyama, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan
- P1-02 Mono Total in Lung Cancer
Ewa Wójcik, Center of Oncology, Poland
- P1-03 Relations between VEGF and Nutrition and Inflammation Indices in SCLC Patients
Ewa Wójcik, Center of Oncology, Poland
- P1-04 Clinical Utility of Tumor Markers and Cytokines Assessment in Patients with Bladder Cancer
Malgorzata Fuksiewicz, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland
- P1-05 [-2]pro PSA Significantly Improves Prostate Cancer Detection
Carsten Stephan, Charité - Universitätsmedizin Berlin, Germany
- P1-06 Upregulated Expression of Survivin and Its Splice Variants in Non-small Cell Lung Carcinoma
Evzen Krepela, University Hospital Bulovka, Czech Republic
- P1-07 Sensitive Detection of Fibroblast Growth Factor Receptor 3 Gene Mutations in Urothelial Cell Carcinoma of the Bladder and Urine Sediments by Peptide Nucleic Acid-mediated Real-Time PCR clamping
Makito Miyake, Tochigi Cancer Center Research Institute and Nara Medical University, Japan
- P1-08 Pamidronate Decreases Protein Kinase C Expression in Prostate Cancer PC-3 Cells
Kazuhiro Fukami, Gifu Pharmaceutical University, Japan
- P1-09 Circulating Serum Vascular Endothelial Growth Factor in Non Small Cell Lung Cancer: a 13-year Retrospective Study
Pierre-Jean Lamy, Centre de Lutte Contre le Cancer Val d'Aurelle-Paul Lamarque, France
- P1-10 The Importance that has the Search of the Expression of Somatostatin's Receptors in Lung's Cancers is Supported by The Abundant Diagnostic and Clinical Implications that Such an Information Involves
Buda Francesco, City of Udine Hospital, Italy
- P1-11 Cancelled
- P1-12 Down Regulation of Prostate Specific Antigen by IL-1 Beta in Prostatic Cancer Cell Line, LNCaP
Bouraoui Mechergui Y, Unit Unit Immuno-Microbio Environmental and Carcinogenesis (IMEC), Tunisia

15:30-16:00 Poster Session 2

New Therapy and New Marker 1

- P2-01 Surface Membrane Glycosylation and Cell Death Affected by Free or *N*-(2-hydroxypropyl) Methacrylamide Bound Doxorubicin in EL-4 Cells
Lubomir Kovář, Institute of Microbiology ASCR v.v.i., Czech Republic
- P2-02 Oncomarkers (NSE, S-100B, GFAP, neurofilaments) Facilitated Monitoring of Fluid Permeability-related Changes of Brain Barrier: A Study of Traumatic Perilesional Brain Oedema
David Vajtr, Charles University and University Hospital Motol, Czech Republic
- P2-03 Serum Bone Turnover Markers: PINP, Osteocalcin and β -Ctx, in Adult Bone Sarcoma Patients
Beata Kotowicz, Maria Sklodowska-Curie Memorial Cancer Center, Poland
- P2-04 Sinergistic Therapeutic Effect of IL-2/anti-IL-2 mAb Complexes and Polymer-bound Doxorubicin Leads to Significantly Prolonged Survival of Mice
Jakub Tomala, Academy of Sciences of the Czech Republic, Czech Republic
- P2-05 Effect of Cisplatin on Metallothionein Level in Rats
David Vajtr, Charles University, Czech Republic
- P2-06 Metallothionein as a Marker of Spinocellular Carcinoma
David Vajtr, Charles University, Czech Republic
- P2-07 A Chemiluminescent Microparticle HE4 Assay for the ARCHITECT® Instrument System
Olle Nilsson, Fujirebio Diagnostics AB, Sweden
- P2-08 Gene Expression at Cell Cycle Exit.
Magdalena Chechlinska, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Poland
- P2-09 Prognostic Factor of B-cell Chronic Lymphocytic Leukemia (B-CLL): Correlation between CD38 Expression, Survival Probability and IgVH Mutational Status
Buda Francesco, City of Udine Hospital, Italy
- P2-10 Diagnosis of Epithelial Tumors Using Monoclonal Antibody as a Tumor Marker
Vinit Mehrotra, Himalayan Institute of Medical Sciences, Dehradun and S. N. Medical College, India

Tuesday, October 7

11:00-11:30 Poster Session 3

Gastrointestinal Carcinoma 1

- P3-01 Metalloproteinases (MMPs) and their Tissue Inhibitors (TIMPs) in Tumors and Plasma of Gastric and Colorectal Cancer Patients: Relationship and Clinico-Pathologic Implication
Elena S. Gershtein, Russian N.N.Blokhin Cancer Research Center RAMS, Russia
- P3-02 Formation of Precursor Cells of Preneoplastic Foci via Nongenetic Disorganization of Bile Duct Cells in the Initiation Stage of Rat Chemical Hepatocarcinogenesis
Kimihiko Satoh, Hirosaki University, Japan

- P3-03 Clinical Significance of Molecular Markers Expression at the Invasive Front of Colon Carcinomas
Nicolai E. Kushlinsky, Russian N.N. Blokhin Cancer Research Centre RAMS, Russia
- P3-04 Rho Kinase is Increased in Tumor Surrounding Liver Tissue with Hepatocellular Carcinoma Patients
Toshio Kumai, St. Marianna University School of Medicine, Japan
- P3-05 Microsatellite Instability, Methylation and Mutation Analysis in Colorectal Cancer
Anna Krepelova, University Hospital Motol and Charles University, Czech Republic
- P3-06 Establishment of Primary Culture System of Hepatocellular Carcinoma and Pancreatic Cancer on NanoCulture Plate
Manami Shimomura, National Cancer Center Hospital East, Japan
- P3-07 Induction of Metastatic Potential by Cleavage of Carcinoembryonic Antigen in Colorectal Carcinoma Cells
Kaori Iwaki, Osaka University, Japan
- P3-08 Intermediate Surrogate Molecular Marker for the Prevention of Colorectal Cancer
Yukiko Ueno, Osaka University, Japan
- P3-09 Transcriptional Silencing of Dickkopf Gene Family by CpG Island Hypermethylation in Human Gastrointestinal Cancer
Tadateru Maehata, St. Marianna University School of Medicine, Japan
- P3-10 Olfactomedin 4 and Reg IV: Novel Serum Biomarkers for Gastric Cancer Patients
Naohide Oue, Hiroshima University Graduate School of Biomedical Sciences, Japan
- P3-11 Characteristics of Colon Cancer-Initiating Cells
Hideshi Ishii, Kyushu University and Osaka University, Japan
- P3-12 PAPP-A (IGFBP-4 protease) in Colorectal Carcinomas Presenting
Christian Ensinger, Medical University of Innsbruck, Austria

Wednesday, October 8

11:00-11:30 Poster Session 4

New Therapy and New Marker 2

- P4-01 Efficacy of Anti-HIFPH3 Autoantibody as a Serological Marker for Renal Cell Carcinoma
Toshiaki Tanaka, Sapporo Medical University, Japan
- P4-02 A New RECAF ELISA and Its Correlation with the Chemiluminescence RECAF Assay
Ricardo Moro, BioCurex, Canada
- P4-03 Specific Binding of Fibroblast Growth Factor-1 (FGF1) to Integrins is Required for FGF1 Signaling
Seiji Mori, Osaka University, Japan
- P4-04 Characterization of Release of Caspase-cleaved CK18 from Tumor Cells into Blood
Maria Hagg Olofsson, Karolinska Institute and Hospital, Sweden
- P4-05 Dissection of Glycotopes Carried by Soluble CD44-variants in Sera of Patients with Cancers
Reiji Kannagi, Research Institute, Aichi Cancer Center, Japan

- P4-06 A Novel Strategy to Identify Oncofetal Antigens by Acreening a Hybridoma Library Raised Against Human Embryonic Stem Cells
Olle Nilsson, Fujirebio Diagnostics AB, Sweden
- P4-07 Divergent Roles of Tumor Suppressor Gene Klf6 in ES Cell Differentiation
Nobuyuki Matsumoto, St. Marianna University School of Medicine, Japan and Mount Sinai School of Medicine, USA
- P4-08 Automated Immunoassay for Pro-gastrin-releasing Peptide (ProGRP)
Eiji Kobayashi, Abbott Japan, Japan
- P4-09 p53 Expression with p21 Suppression by Single Vector Enhances Antitumor Effect
Masashi Idogawa, Sapporo Medical University, Japan
- P4-10 Apoptotic Tumor Suppression Effect of Anti-erbB-2 Chimeric Monoclonal Antibody
Masayuki Tsujisaki, Tenshi Hospital, Japan
- P4-11 Biological Activity and Dynamic Properties of Human Alpha-Fetoprotein-Derived Peptide LDSYQCT
Alexander A. Terentiev, Russian State Medical University, Russia
- P4-12 Short AFP-Like Motifs as Markers for Regulation of Cell Fate by Polypeptide Growth Factors and Proteins with EGF-Like Modules
Alexander A. Terentiev, Russian State Medical University, Russia
- P4-13 Biological Effects of PSG- and CEA-Derived Oligopeptide Fragments
Alexander A. Terentiev, Russian State Medical University, Russia

15:30-16:00 Poster Session 5

Squamous Cell Carcinoma and Gynecology Cancer

- P5-01 Diagnostic Usefulness of SCC-Ag, Cyfra 21-1, MonoTotal, and Selected Acute Phase Proteins in Head and Neck Cancer Patients
Zofia Stasik, Center of Oncology, Poland
- P5-02 Blood Based Gene Expression Test for Early Detection of Breast Cancer
Ken Bårdsen, DiaGenic ASA, Norway
- P5-03 Bone Turnover Markers in Diagnosis and Prognosis of Metastatic Bone Disease in Breast Cancer Patients
Nina V. Lyubimova, Russian N.N. Blokhin Cancer Research Center, Russia
- P5-04 Novel Molecular Method for Rapid Diagnosis of Lymph Node Metastasis in Breast Cancer
Mohammed N. Shaker, Osaka University, Japan
- P5-05 Effect of Platelet Derived Growth Factor on Development and Progression of Breast Cancer
Yuhki Yokoyama, Osaka University, Japan
- P5-06 Immunohistochemical Evaluation of Thymidylate Synthase, Dihydropyrimidine Dehydrogenase and p53 for Combination of S-1/Nedaplatin and Radiotherapy in Esophageal Cancer
Takashi Tsuda, St. Marianna University School of Medicine, Japan
- P5-07 Cancelled

- P5-08 Immunohistochemical Analysis and Serum Concentration of Reg IV in Patients with Esophageal Cancer
Katsuhiko Anami, Hiroshima University Graduate School of Biomedical Sciences, Japan
- P5-09 Aneuploidy predicts Outcome in Patients with Endometrial Carcinoma and is Related to Lack of *CDH13* Hypermethylation
Yutaka Suehiro, Yamaguchi University Graduate School of Medicine, Japan
- P5-10 Serum HER-2 as an Early Predictor of Disease Relapse in Breast Cancer
Diana P. Soerensen, Vejle County Hospital, Denmark

Thursday, October 9

10:20-10:50 Poster Session 6

Gastrointestinal Carcinoma 2

- P6-01 Evaluation of Adipokine in Non Alcoholic Fatty Liver Disease -Comparison with Alcoholic Liver Disease-
Hideaki Takahashi, St. Marianna University School of Medicine, Japan
- P6-02 Evaluation of Relevance between Expression of mTOR Signal Pathway Markers and Clinicohistopathological Features in Colorectal Tumor
Masaru Okamoto, St. Marianna University School of Medicine, Japan
- P6-03 Usefulness of Gemcitabine Therapy for Elderly Patients of Unresectable Pancreatic Cancer
Yoshiki Katakura, St. Marianna University School of Medicine, Japan
- P6-04 Expression of Nestin and Pancreatic Fibrosis in a Spontaneous Chronic Pancreatitis Model (Male WBN/Kob Rats)
Ryujiro Negishi, St. Marianna University School of Medicine, Japan
- P6-05 Anti-tumor Efficacy of Anti-FGFR1 Monoclonal Antibody for Human Hepatoma Cells
Shigeru Sasaki, Sapporo Medical University, Japan
- P6-06 Genomic Mapping of 12p Amplifications in Gastric Cancer Reveal a 0.5-Mb Target Region Including KRAS Locus
Hiroaki Mita, Sapporo Medical University, Japan
- P6-07 Can CEA be a Risk Factor for Recurrence in Stage II Colon Cancer?
Toshiyuki Suwa, St. Marianna University School of Medicine, Japan
- P6-08 An Update of a Phase I/II Trial of FOLFIRI for Colorectal Cancer Patients with Pharmacogenetic/Pharmacokinetic Analysis
Keishi Yamashita, Saitama Medical University, Japan
- P6-09 LINE-1 Hypomethylation is Associated with Increased CpG Island Methylation in H.pylori-related Enlarged Fold Gastritis
Masanori Nojima, Sapporo Medical University, Japan
- P6-10 Oncogenic Role of KIAA0101 Interacting with Proliferating Cell Nuclear Antigen in Pancreatic Cancer
Masayo Hosokawa, Sapporo Medical University, Japan
- P6-11 *ABCC2* Genotype is a Biomarker of Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with FOLFIRI
Fumio Nagashima, Saitama Medical University, Japan